EP1705992A1 - Intratumoral delivery of dendritic cells - Google Patents
Intratumoral delivery of dendritic cellsInfo
- Publication number
- EP1705992A1 EP1705992A1 EP04703716A EP04703716A EP1705992A1 EP 1705992 A1 EP1705992 A1 EP 1705992A1 EP 04703716 A EP04703716 A EP 04703716A EP 04703716 A EP04703716 A EP 04703716A EP 1705992 A1 EP1705992 A1 EP 1705992A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- tumor
- dendritic cells
- mammal
- cells
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004443 dendritic cell Anatomy 0.000 title claims abstract description 169
- 230000002601 intratumoral effect Effects 0.000 title description 13
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 137
- 238000000034 method Methods 0.000 claims abstract description 87
- 241000124008 Mammalia Species 0.000 claims abstract description 43
- 239000000203 mixture Substances 0.000 claims abstract description 31
- 208000003174 Brain Neoplasms Diseases 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 24
- 230000008595 infiltration Effects 0.000 claims abstract description 14
- 238000001764 infiltration Methods 0.000 claims abstract description 14
- 210000002865 immune cell Anatomy 0.000 claims abstract description 5
- 210000001519 tissue Anatomy 0.000 claims description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 21
- 238000011081 inoculation Methods 0.000 claims description 21
- 239000011780 sodium chloride Substances 0.000 claims description 21
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 12
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 12
- 102000004388 Interleukin-4 Human genes 0.000 claims description 10
- 108090000978 Interleukin-4 Proteins 0.000 claims description 10
- 210000004556 brain Anatomy 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 10
- 229940028885 interleukin-4 Drugs 0.000 claims description 10
- 238000003306 harvesting Methods 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 210000001185 bone marrow Anatomy 0.000 claims description 8
- 238000001959 radiotherapy Methods 0.000 claims description 7
- 210000000952 spleen Anatomy 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 5
- 210000000481 breast Anatomy 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 210000002345 respiratory system Anatomy 0.000 claims description 3
- 238000002672 stereotactic surgery Methods 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 230000006698 induction Effects 0.000 abstract description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 31
- 238000002255 vaccination Methods 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 22
- 238000007917 intracranial administration Methods 0.000 description 20
- 206010018338 Glioma Diseases 0.000 description 19
- 241000700159 Rattus Species 0.000 description 19
- 102000036639 antigens Human genes 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 239000000427 antigen Substances 0.000 description 15
- 208000032612 Glial tumor Diseases 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 102100037850 Interferon gamma Human genes 0.000 description 11
- 108010074328 Interferon-gamma Proteins 0.000 description 11
- 210000000612 antigen-presenting cell Anatomy 0.000 description 11
- 210000001165 lymph node Anatomy 0.000 description 10
- 210000001616 monocyte Anatomy 0.000 description 10
- 238000002513 implantation Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 8
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 8
- 239000005090 green fluorescent protein Substances 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 230000037452 priming Effects 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000005809 anti-tumor immunity Effects 0.000 description 4
- 210000004227 basal ganglia Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 3
- 210000001653 corpus striatum Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000006023 anti-tumor response Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000001142 back Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 208000029824 high grade glioma Diseases 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000003447 ipsilateral effect Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 201000011614 malignant glioma Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
Definitions
- the present invention relates to methods of treating a tumor by administering dendritic cells and compositions effective for the same. More specifically, the method involves administering dendritic cells directly into a tumor or its surrounding tissue, the tumor being located in the body of a mammal.
- the compositions are dendritic cell-based.
- BACKGROUND OF THE INVENTION Cancer remains one of the leading causes of death in the United States and around the world.
- Various forms of cancer are differentially treated, depending in part on the location of a tumor targeted for treatment.
- One particularly difficult group of tumors to treat are those that reside in and near the brain.
- Treatment of brain tumors presents a number of problems, not the least of which being the dangers inherent in any surgical procedure involving regions of the brain and the tissue located nearby. There is little room for error and the consequences of even a minor surgical mishap can be devastating to a patient; brain damage, or even death may result.
- surgery remains the preferred method of treatment for most brain tumors and is often performed in conjunction with radiation therapy and chemotherapy.
- Glioblastoma multiforme and anaplastic astrocytomas are classified in the category of brain tumors commonly known as malignant gliomas. Although not particularly common tumors themselves, they represent a class of tumors associated with significant rates of mortality and morbidity.
- Current treatment for malignant glioma consists of surgical resection followed by radiation therapy and chemotherapy. However, this treatment generally fails in substantially changing the outcome for a patient; median survival remains less than one year even with medical intervention. Inducing the body's immune system to specifically combat tumor cells may ultimately be the only means of completely eliminating these cells.
- T-cells recognize the digested fragments and bind to the APCs; this activates the T-cells and triggers the immune response.
- Some studies suggest that tumor cells themselves may contain immunogeneic antigens. However, these studies further note that tumor cells are poor APCs; they do not efficiently internalize and process/present tumor antigens to T-cells. S. Constant et al., "Peptide and protein antigens require distinct antigen-presenting cell subsets for the priming of CD4+ T cells," J. Immunol. 154:4915-4923 (1995); D. Levin et al. , "Role of dendritic cells in the priming of CD4+ lymphocytes to peptide antigen in vivo," J.
- IL-4 interleukin-4
- TGF- ⁇ transforming growth factor- ⁇
- GM-CSF granulocyte- macrophage colony-stimulating factor
- Dendritic cells are "professional APCs," as they are uniquely capable of activating both primed T-cells (as in the case of macrophages and B-cells) and na ⁇ ve T-cells (i.e., those that have not previously encountered antigens). In fact, dendritic cells are the only APCs known to process exogenous antigen through the class I pathway. Thus, efforts have been directed toward determining whether dendritic cells presenting tumor- associated antigens can mediate a significant anti-tumor response; potentially an anti- tumor response stronger than that induced by cytokine-presenting cells.
- cytokine-stimulated dendritic cells have been pulsed ex vivo with tumor antigens and used successfully as anti-tumor vaccines for extracranial tumor models.
- J. Mayorodomo et al. "Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity," Nature Med. 1 :1297-1302 (1995); J. Young and K. Inaba, "Dendritic cells and adjuvants for class I major histocompatability complex-restricted antitumor immunity," J. Exp. Med. 183:7-11 (1996); L.
- a tumor may be surgically inaccessible, or the surgical manipulation thereof may present unreasonable danger to the health and safety of a patient. Even in instances where tumor tissue can be readily accessed and sampled, the surgical harvest required to obtain that tissue subjects a patient to yet another procedure, the avoidance of which is likely desirable.
- a system and method of implementing a dendritic cell-based vaccination strategy that obviates, for practical purposes, the above- mentioned limitations. More specifically, there is a need in the art for a composition including and method for implementing a dendritic cell-based vaccination strategy to treat a tumor without the need for ex vivo priming of the dendritic cells prior to administration of the same to a patient.
- the present invention provides a method and dendritic cell-based composition for treating a tumor.
- the method may include administering dendritic cells directly into the tumor itself or into the tissue surrounding or located nearby the tumor, and may be effective in the treatment of a tumor disposed in any location throughout the body of a mammal.
- the method and composition do not require the dendritic cells used therein to be primed ex vivo prior to inclusion in the composition or administration to a patient.
- the methods of the present invention may induce immune cell infiltration into a tumor.
- Figure 1 depicts a phenotypic profile of dendritic cells in accordance with an embodiment of the present invention. Bone marrow cultures yielded cells expressing cell surface phenotypic markers that dendritic cells commonly express.
- Figure 2 depicts an inhibition of tumor growth owing to intratumoral dendritic cell vaccination in accordance with an embodiment of the present invention.
- Dendritic cells (Column B) and a saline control (Column A) were vaccinated into subcutaneous 9L glioma tumors on the dorsum of the foot. Tumor volume was markedly lower when treated with dendritic cells.
- Figure 3 depicts an intratumoral vaccination with dendritic cells inducing T-cell infiltration into brain tumors in accordance with an embodiment of the present invention. Dendritic cells vaccinated into brain tumors induce increased CD4+ T-cell infiltration (Fig. 3A) as compared to saline-treated controls (Fig. 3B).
- Figure 4 depicts an intracranial dendritic cell vaccination prolonging survival in accordance with an embodiment of the present invention.
- FIG. 5 depicts an intracranial dendritic cell vaccination prolonging survival in animals with established intracranial gliomas in accordance with an embodiment of the present invention.
- 9L glioma-bearing rats survived longer than monocyte-inoculated controls.
- Figure 6 depicts a promotion of T-cell infiltration in 9L intracranial gliomas inoculated with dendritic cells in accordance with an embodiment of the present invention. Strong T-cell infiltration was observed in animals vaccinated with dendritic cells (Fig. 6A) and weak infiltration was observed in monocyte-treated (Fig. 6B) and saline-treated (Fig. 6C) controls. R2 indicates region of CD8+ staining and R3 indicates region of CD4+ staining.
- Figure 7 is executed in color and depicts a migration of dendritic cells into systemic lymph nodes in accordance with an embodiment of the present invention. Dendritic cells expressing green fluorescent protein (GFP) were found dispersed within the main tumor mass (Fig.
- GFP green fluorescent protein
- FIG. 7A depicts an enhancement of tumor-specific cytotoxic T-cell activity by intratumoral inoculation of dendritic cells into intracranial brain tumors in accordance with an embodiment of the present invention.
- T-cells from animals inoculated with dendritic cells demonstrated a 1.48-fold increase in IFN-gamma RNA message compared to monocyte-treated (1.12-fold) and saline-treated (1.20-fold) controls.
- Figure 9 depicts an enhancement of tumor-specific cytotoxic T-cell activity by intratumoral inoculation of dendritic cells into intracranial brain tumors in accordance with an embodiment of the present invention.
- T-cells from animals inoculated with dendritic cells demonstrated a 1.31 -fold increase in secreted IFN-gamma compared to monocyte- treated (0.70-fold) and saline-treated (1.10-fold) controls.
- the present invention is based upon a composition for and method of treating a tumor by injecting or otherwise administering dendritic cells into the tumor or its immediately surrounding tissue (hereinafter, a tumor and its immediately surrounding tissue are collectively included in the term "tumor region"). More specifically, the method involves injecting or otherwise administering the dendritic cells directly into a solid tumor. Treating a tumor in accordance with the embodiments of the present invention provides dendritic cells with more direct access to the tumor than that which is possible with conventional methods; especially those conventional methods wherein dendritic cells are administered peripherally.
- the techniques of the present invention may be particularly advantageous in instances where a tumor is surgically inoperable, where surgery is otherwise undesirable, or where no portion of the tumor can be retrieved for priming dendritic cells ex vivo against the tumor; although such factors need not be indicated in order for the methods of the present invention to be effective.
- the methods of the present invention may be especially advantageous in the treatment of tumors located in the brain of a mammal; particularly in treating high- or low-grade malignant gliomas, and, even more particularly, in treating anaplastic astrocytoma or glioblastoma multiforme.
- composition and methods of the present invention are based, in part, on the inventors' surprising discovery that unprimed dendritic cells may be delivered to the tumor region of a patient and may thereafter be effective in the treatment of the tumor. Dendritic cells administered in this manner essentially prime themselves in vivo upon coming into contact or otherwise establishing biochemical communication with the target tumor cells, and, correspondingly, their antigen proteins.
- Unprimed dendritic cells include those dendritic cells that do not rely upon the acquisition of tumor tissue as a protein source, and the subsequent culturing therewith.
- dendritic cells are primed ex vivo. This generally involves culturing the dendritic cells with the tumor cells against which they will subsequently be utilized. This process provides the dendritic cells access to the tumor proteins, thereby allowing the cells to process the associated tumor antigens and prepare to present the digested antigens to T-cells upon introduction of the dendritic cells to the body of a patient.
- dendritic cells may be delivered directly into a tumor bed or tumor region without first being primed ex vivo; the dendritic cells process the tumor antigens only in vivo.
- Dendritic cells suitable for use in accordance with the present invention may be isolated or obtained from any tissue in which such cells are found, or may be otherwise cultured and provided.
- antigen-presenting dendritic cells are preferred for use in accordance with the methods of the present invention.
- dendritic cells may be found, by way of example, in the bone marrow or peripheral blood mononuclear cells (PBMCs) of a mammal, in the spleen of a mammal, or in the skin of a mammal (i.e., Langerhan's cells, which possess certain qualities similar to that of dendritic cells, may be found in the skin and may further be employed in conjunction with the methods of the present invention, and are included within the scope of the term "dendritic cells” as used herein).
- PBMCs peripheral blood mononuclear cells
- Langerhan's cells which possess certain qualities similar to that of dendritic cells
- bone marrow may be harvested from a mammal and cultured in a medium.
- Any suitable medium that promotes the growth of dendritic cells may be used in accordance with the present invention, and may be readily ascertained by one of skill in the art without undue experimentation.
- GM-CSF and/or IL-4 may be included in the above-described medium.
- Media may be at least partially replenished every few (e.g., two to four) days during the culturing process. After a suitable amount of time, clusters of dendritic cells may be apparent in the medium, and may be retrieved therefrom, either in individual clusters or in any other convenient amount.
- Dendritic cells used in conjunction with the methods of the present invention may be delivered to a tumor region (e.g., a brain tumor, or the surrounding brain tissue) in a recipient by any suitable means. Such means of delivery may include, but are in no way limited to, injection, infusion, inoculation, direct surgical delivery, or any combination thereof.
- dendritic cells may be administered to a mammal by direct inoculation via stereotactic surgery; a standard inoculation procedure known to those of skill in the art of neurosurgery.
- the composition of the present invention may include unprimed dendritic cells in a pharmaceutical carrier.
- Any conventional pharmaceutical carrier may be used in accordance with the composition or methods of the present invention, and an appropriate carrier may be selected by one of skill in the art without undue experimentation.
- the pharmaceutical carrier is saline, although other carriers may be utilized depending upon the desired characteristics of the composition.
- the dendritic cells administered to a patient in accordance with the composition and methods of the present invention may be delivered in combination with any of a variety of additional substances and compounds.
- the dendritic cells of the present invention may be administered to a patient along with any suitable carrier, vehicle, additive, excipient, pharmaceutical adjunct, or other suitable product, as will be readily ascertained and appreciated by one of skill in the art.
- the dendritic cells of the present invention may be administered in conjunction with other therapeutic compounds or agents useful in the treatment of the tumor or the relief of pain associated with the tumor or treatment thereof.
- the quantity of dendritic cells appropriate for administration to a patient to effect the methods of the present invention and the most convenient route of such administration may be based upon a variety of factors, as may the formulation of the composition of the present invention .
- a patient may be administered with from about 10 5 to about 10 7 dendritic cells in from about 0.05 mL to about 0.30 mL saline in a single administration.
- a mammal is treated with dendritic cells following or in conjunction with radiotherapy. While not wishing to be bound by any theory, it is believed that prior or simultaneous treatment with radiotherapy renders a dendritic cell vaccination more effective as is allows the dendritic cells to better process dying tumor cells. Similarly, a chemotherapy regimen administered either prior to or simultaneous with dendritic cell vaccination therapy that induces tumor cells to undergo apoptosis (i.e., programmed cell death) may be beneficial.
- treating includes, but is not limited to, ameliorating the tumor, lessening the severity of its complications, causing it to decrease in mass and/or size, preventing it from manifesting, preventing it from recurring, merely preventing it from worsening, or a therapeutic effort to effect any of the aforementioned, even if such therapeutic effort is ultimately unsuccessful.
- EXAMPLES The Examples discussed herein demonstrate that dendritic cells may inhibit the growth of brain tumors when implanted directly into the tumors, and that this treatment may prolong the life of a patient with a brain tumor. The Examples further illustrate that dendritic cell vaccination may induce immune cell infiltration into brain tumors and systemic lymph nodes. Moreover, the Examples show that the implantation of dendritic cells directly into tumors disposed in locations throughout the body of a mammal is effective in the treatment of the same.
- EXAMPLE 2 Dendritic Cells Inhibit Tumor Growth when Inoculated Intratum orally Dendritic cells were inoculated subcutaneously along with a mixture of irradiated and viable 9L glioma cells into the dorsum of the right foot of adult Fisher rats . Two weeks following this procedure, a second dose of dendritic cells was inoculated into each growing tumor. Eight weeks following t ie second dendritic cell vaccination, tumor sizes were measured using a precision caliper. Tumors were markedly smaller in animals that had received intratumoral dendritic cell as compared to the control animals that received only saline inoculations (Fig. 2).
- E.XAMPLE 3 Dendritic Cell Vaccination Induces Immune Cell (T-cell) Infiltration into Brain Tumors
- Dendritic cells were inoculated intracranially along with a mixture of irradiated and viable 9L glioma cells into the right corpus striatum (basal ganglia) of adult Fisher rats. Two weeks following this procedure, a second dose of dendritic cells was inoculated into each growing tumor. Two weeks following the second dendritic cell vaccination, animals were euthanized and their brains harvested. The brains were immediately frozen and sectioned on a cryostat (available from Janis Research Company, Inc.; Wilmington, MA).
- T-cell markers i.e., CD4 and CD8.
- Tumors from dendritic cell vaccinated animals displayed increased quantities of infiltrating T-cells as compared to tumors from control animals that received only saline inoculations (Fig. 3).
- Dendritic cells were inoculated intracranially along with a mixture of irradiated and viable 9L glioma cells into the right corp us striatum (basal ganglia) of adult Fisher rats. Two weeks following this procedure, a second dose of dendritic cells was inoculated into each growing tumor. Control animals were treated at similar time points with intracranial saline inoculations. Animals were followed for survival. Rats treated with intracranial dendritic cell vaccination survived longer than saline treated controls, with 75% of dendritic cell-treated animals surviving beyond 90 days after the initial tumor implantation compared to 5% of the control group (Fig.
- EXAMPLE 5 Dendritic Cell Vaccinations Prolong Survival in Rats with Established Brain Tumors
- a mixture of irradiated and viable 9L glioma cells was introduced into the right corpus striatum (basal ganglia) of adult Fisher rats. Two days later, rats were inoculated intracranially with dendritic cells. Control animals were treated at similar time points with intracranial monocyte/macrophage inoculations. Animals were followed for survival. Rats treated with intracranial dendritic cell vaccination survived longer than monocyte/macrophage-treated controls, with 60% of dendritic cell-treated animals surviving beyond 90 days after the initial tumor implantation compared to 10% of the control group (Fig. 5). Moreover, surviving rats were immune to intracranial tumor re- challenge.
- a mixture of irradiated and viable 9L glioma cells was introduced into the right corpus striatum (basal ganglia) of adult Fisher rats. Rats were vaccinated with intratumoral inoculations of immature dendritic cells, monocytes, or saline on days 2 and 16 following tumor implantation. One week following the second intratumoral inoculation, tumors were harvested and stained for CD4+ and CD8+ T-cell content. Results indicated strong T-cell infiltration in animals vaccinated with dendritic cells (Fig. 6A) and weak infiltration in monocyte (Fig. 6B) and saline (Fig. 6C) treated controls.
- EXAMPLE 7 Dendritic Cells Migrate to Systemic Lymph Nodes To assess whether dendritic cells inoculated into intracranial brain tumors could drain to the lymphatic system, deep cervical lymph nodes were harvested from rats that had received intracranial co-implantations of partially irradiated 9L glioma cells and green fluorescent protein (GFP) expressing dendritic cells four days earlier. Tumor bearing brain sections from these animals demonstrated GFP positive dendritic cells interspersed within the main tumor mass (Fig. 7A). Deep cervical lymph nodes ipsilateral to the site of implantation were infiltrated with numerous GFP expressing cells (Fig. 7B). In contrast, contralateral cervical lymph node tissue (not shown) or lymph nodes from 9L glioma bearing rats not inoculated with dendritic cells (Fig. 7C) did not reveal any GFP positivity.
- GFP green fluorescent protein
- EXAMPLE 8 Enhancement of Tumor-Specific Cytotoxic T-cell Activity with Dendritic Cell Inoculation, Measured by Increased IFN-gamma Message
- T-cells were isolated from their spleens two weeks following the second intratumoral inoculation. Harvested T-cells were re-stimulated in quadruplicate in vitro with irradiated 9L glioma cells.
- PCR polymerase chain reaction
- a cycle difference of 1 was assumed to indicate a two-fold difference in the message.
- a fold-increase in IFN-gamma message for each treatment group was calculated by comparing target with no target.
- T-cells from animals inoculated with dendritic cells demonstrated a 1.48-fold increase in IFN-gamma RNA message compared to monocyte (1.12-fold) and saline (1.20-fold) treated controls.
- EXAMPLE 9 Enhancement of Tumor-Specific Cytotoxic T-cell Activity with Dendritic Cell Inoculation, Measured by Increased IFN-gamma Secretion
- T-cells were isolated from their spleens two weeks following the second intratumoral inoculation. Harvested T-cells were re-stimulated in quadruplicate in vitro with irradiated 9L glioma cells.
- a fold-increase in IFN-gamma levels for each treatment group was calculated by comparing target with no target.
- T-cells from animals inoculated with dendritic cells demonstrated a 1.31-fold increase in secreted IFN-gamma compared to monocyte (0.70-fold) and saline (1.10-fold) treated controls.
- the protease inhibitors of the present invention may be used in the treatment of any number of conditions where inflammation is observed, as would be readily recognized by one skilled in the art and without undue experimentation.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Methods included herein describe the treatment of a tumor by administering dendritic cells either directly into the same or into its surrounding tissue. Further methods describe the induction of immune cell infiltration into tumors and the treatment of tumors with unprimed dendritic cells by administering dendritic cells in a similar fashion. The methods of the present invention are particularly advantageous in the treatment of brain tumors and other solid tumors disposed throughout the body of a mammal that are difficult or impossible to treat by conventional surgical means. Dendritic cell-based compositions effective in the treatment of such tumors are also described.
Description
INTRATUMORAL DELIVERY OF DENDRITIC CELLS
FIELD OF THE INVENTION The present invention relates to methods of treating a tumor by administering dendritic cells and compositions effective for the same. More specifically, the method involves administering dendritic cells directly into a tumor or its surrounding tissue, the tumor being located in the body of a mammal. The compositions are dendritic cell-based.
BACKGROUND OF THE INVENTION Cancer remains one of the leading causes of death in the United States and around the world. Various forms of cancer are differentially treated, depending in part on the location of a tumor targeted for treatment. One particularly difficult group of tumors to treat are those that reside in and near the brain. Treatment of brain tumors presents a number of problems, not the least of which being the dangers inherent in any surgical procedure involving regions of the brain and the tissue located nearby. There is little room for error and the consequences of even a minor surgical mishap can be devastating to a patient; brain damage, or even death may result. Still, where possible, surgery remains the preferred method of treatment for most brain tumors and is often performed in conjunction with radiation therapy and chemotherapy. However, even commonly referenced medical authority suggests that patients with brain tumors be referred to centers specializing in investigative therapies; an indication that conventional modes of treatment are not overwhelmingly successful. Glioblastoma multiforme and anaplastic astrocytomas are classified in the category of brain tumors commonly known as malignant gliomas. Although not particularly common tumors themselves, they represent a class of tumors associated with significant rates of mortality and morbidity. Current treatment for malignant glioma consists of surgical resection followed by radiation therapy and chemotherapy. However, this treatment generally fails in substantially changing the outcome for a patient; median survival remains less than one year even with medical intervention. Inducing the body's immune system to specifically combat tumor cells may ultimately be the only means of completely eliminating these cells. Such an immunotherapy approach was attempted over a decade ago, by treating cancer patients
with a combination of recombinant human interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells. Although this form of immunotherapy was well-tolerated by patients, therapeutic attempts implementing the same have thus far not led to the identification of a superior treatment or cure. More recent studies have focused on other means of initiating and promulgating an immune response by activating T-cells and targeting the same against infiltrative tumor cells. Generally, the body's immune response is initiated when antigen presenting cells (APCs) digest an antigen into fragments, and subsequently present this digested antigen to T-cells. T-cells recognize the digested fragments and bind to the APCs; this activates the T-cells and triggers the immune response. Some studies suggest that tumor cells themselves may contain immunogeneic antigens. However, these studies further note that tumor cells are poor APCs; they do not efficiently internalize and process/present tumor antigens to T-cells. S. Constant et al., "Peptide and protein antigens require distinct antigen-presenting cell subsets for the priming of CD4+ T cells," J. Immunol. 154:4915-4923 (1995); D. Levin et al. , "Role of dendritic cells in the priming of CD4+ lymphocytes to peptide antigen in vivo," J. Immunol. 151:6742-6748 (1993). Thus, additional support and/or stimulation is required to trigger a more substantial and effective immune response. To aid in the stimulation of such an immune response and to increase tumor cell immunogenicity, vaccination with genetically engineered cells expressing a variety of cytokines has been attempted. Cytokines are known to induce immune and inflammatory responses, and various studies have shown these responses to exhibit an anti-tumor effect. G. Dranoff et al., "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity," Proc. Natl. Acad. Sci. USA 90:3539-3543 (1993). Moreover, it is believed that this anti-tumor effect is initiated by the cytokines' role in antigen presentation through recruitment of APCs such as macrophages and B- cells, which can, in turn, activate primed T-cells. For instance, treatment modalities involving interleukin-4 (IL-4), transforming growth factor-β (TGF-β), and granulocyte- macrophage colony-stimulating factor (GM-CSF) have each been successfully examined for an anti-tumor effect. In fact, GM-CSF has been identified as the most potent cytokine for achieving brain tumor-specific immunity, when cells expressing this cytokine are vaccinated peripherally. Dranoff et al. at 3539. Although the isolation of a ubiquitous
tumor antigen has been elusive, by vaccinating peripherally with cells expressing various cytokines, the body's immune response may be triggered and targeted against an intracranial tumor. However, intracranial vaccination with cytokine-expressing cells is not clinically implemented, as intracranial cytokine expression presents a host of potential complications, such as the undesirable induction of an inflammatory response within the brain that is not targeted against tumor cells. Although B-cells, macrophages, and other APCs recruited by cytokines may aid in the activation of an immune response, the most potent APCs in the body are dendritic cells. Dendritic cells are "professional APCs," as they are uniquely capable of activating both primed T-cells (as in the case of macrophages and B-cells) and naϊve T-cells (i.e., those that have not previously encountered antigens). In fact, dendritic cells are the only APCs known to process exogenous antigen through the class I pathway. Thus, efforts have been directed toward determining whether dendritic cells presenting tumor- associated antigens can mediate a significant anti-tumor response; potentially an anti- tumor response stronger than that induced by cytokine-presenting cells. In murine models and in two published clinical trials, cytokine-stimulated dendritic cells have been pulsed ex vivo with tumor antigens and used successfully as anti-tumor vaccines for extracranial tumor models. J. Mayorodomo et al., "Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity," Nature Med. 1 :1297-1302 (1995); J. Young and K. Inaba, "Dendritic cells and adjuvants for class I major histocompatability complex-restricted antitumor immunity," J. Exp. Med. 183:7-11 (1996); L. Zitvogel θt al., "Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1 -associated cytokines," J. Exp. Med. 183:87-97 (1996); F. Hsu et al., "Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells," Nature Med. 2:52-58 (1996); and F.O. Nestle et al., "Vaccination of melanoma patients with peptide- or tumor-lysate pulsed dendritic cells," Nature Med. 4:328-332 (1998). In addition, another study demonstrated the use of tumor peptide-pulsed APCs to successfully treat a murine model of a metastatic intracranial tumor model. D.M. Ashley et al., "Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous systems tumors," J. Exp. Med. 186:1177-1182 (1997). Moreover, dendritic cell vaccination in human brain tumor patients has demonstrated encouraging results. J.S. Yu et al., "Vaccination of Malignant
Glioma Patients with Peptide-pulsed Dendritic Cells Elicits Systemic Cytotoxicity and Intracranial T-cell Infiltration," Cancer Res. 61:842-847 (2001). The key limitation in each of these dendritic cell-based vaccination strategies is their reliance on the acquisition of tumor tissue as a protein source for use in priming dendritic cells ex vivo. Priming generally involves culturing the dendritic cells with the tumor cells against which they will subsequently be utilized. This process provides the dendritic cells access to the tumor proteins, thereby allowing the cells to process the associated antigens in preparation for presentation of the digested antigens to T-cells upon administration to a patient. However, priming the dendritic cells in this fashion precludes the use of this therapeutic modality in cases where tumor tissue cannot be readily obtained; a shortcoming frequently encountered with various types of tumors, since a variety of circumstances can render ex vivo priming either impractical or impossible. For instance, a tumor may be surgically inaccessible, or the surgical manipulation thereof may present unreasonable danger to the health and safety of a patient. Even in instances where tumor tissue can be readily accessed and sampled, the surgical harvest required to obtain that tissue subjects a patient to yet another procedure, the avoidance of which is likely desirable. There is therefore a need in the art for a system and method of implementing a dendritic cell-based vaccination strategy that obviates, for practical purposes, the above- mentioned limitations. More specifically, there is a need in the art for a composition including and method for implementing a dendritic cell-based vaccination strategy to treat a tumor without the need for ex vivo priming of the dendritic cells prior to administration of the same to a patient.
SUMMARY OF THE DISCLOSURE The present invention provides a method and dendritic cell-based composition for treating a tumor. The method may include administering dendritic cells directly into the tumor itself or into the tissue surrounding or located nearby the tumor, and may be effective in the treatment of a tumor disposed in any location throughout the body of a mammal. The method and composition do not require the dendritic cells used therein to be primed ex vivo prior to inclusion in the composition or administration to a patient. The methods of the present invention may induce immune cell infiltration into a tumor.
Other features and advantages of the invention will become apparent from the following detailed description, which illustrates, by way of example, various embodiments of the present invention. Certain embodiments may be especially advantageous in the treatment of brain tumors and other solid tumors that are difficult to treat by various conventional means.
BRIEF DESCRIPTION OF THE FIGURES The file of this patent contains at least one drawing executed in color. Copies of this patent with color drawing(s) will be provided by the patent and Trademark Office upon request and payment of the necessary fee. Figure 1 depicts a phenotypic profile of dendritic cells in accordance with an embodiment of the present invention. Bone marrow cultures yielded cells expressing cell surface phenotypic markers that dendritic cells commonly express. Figure 2 depicts an inhibition of tumor growth owing to intratumoral dendritic cell vaccination in accordance with an embodiment of the present invention. Dendritic cells (Column B) and a saline control (Column A) were vaccinated into subcutaneous 9L glioma tumors on the dorsum of the foot. Tumor volume was markedly lower when treated with dendritic cells. Figure 3 depicts an intratumoral vaccination with dendritic cells inducing T-cell infiltration into brain tumors in accordance with an embodiment of the present invention. Dendritic cells vaccinated into brain tumors induce increased CD4+ T-cell infiltration (Fig. 3A) as compared to saline-treated controls (Fig. 3B). Figure 4 depicts an intracranial dendritic cell vaccination prolonging survival in accordance with an embodiment of the present invention. Fisher rats with 9L LacZ brain tumors when treated with intracranial dendritic cell vaccination survived longer than saline-inoculated controls, with 73% (n=18) of the dendritic cell treated animals surviving past 90 days as compared to 8% (n=12) of the controls. Figure 5 depicts an intracranial dendritic cell vaccination prolonging survival in animals with established intracranial gliomas in accordance with an embodiment of the present invention. When vaccinated intracranially with dendritic cells, 9L glioma-bearing rats survived longer than monocyte-inoculated controls. Figure 6 depicts a promotion of T-cell infiltration in 9L intracranial gliomas inoculated with dendritic cells in accordance with an embodiment of the present
invention. Strong T-cell infiltration was observed in animals vaccinated with dendritic cells (Fig. 6A) and weak infiltration was observed in monocyte-treated (Fig. 6B) and saline-treated (Fig. 6C) controls. R2 indicates region of CD8+ staining and R3 indicates region of CD4+ staining. Figure 7 is executed in color and depicts a migration of dendritic cells into systemic lymph nodes in accordance with an embodiment of the present invention. Dendritic cells expressing green fluorescent protein (GFP) were found dispersed within the main tumor mass (Fig. 7A) and within deep cervical lymph nodes ipsilateral to the site of implantation (Fig. 7B); however no appreciable GFP positivity was indicated in contralateral cervical lymph node tissue (not shown) or in lymph nodes from animals not inoculated with dendritic cells (Fig. 7C). Figure 8 depicts an enhancement of tumor-specific cytotoxic T-cell activity by intratumoral inoculation of dendritic cells into intracranial brain tumors in accordance with an embodiment of the present invention. T-cells from animals inoculated with dendritic cells demonstrated a 1.48-fold increase in IFN-gamma RNA message compared to monocyte-treated (1.12-fold) and saline-treated (1.20-fold) controls. Figure 9 depicts an enhancement of tumor-specific cytotoxic T-cell activity by intratumoral inoculation of dendritic cells into intracranial brain tumors in accordance with an embodiment of the present invention. T-cells from animals inoculated with dendritic cells demonstrated a 1.31 -fold increase in secreted IFN-gamma compared to monocyte- treated (0.70-fold) and saline-treated (1.10-fold) controls.
DETAILED DESCRIPTION OF THE INVENTION The present invention is based upon a composition for and method of treating a tumor by injecting or otherwise administering dendritic cells into the tumor or its immediately surrounding tissue (hereinafter, a tumor and its immediately surrounding tissue are collectively included in the term "tumor region"). More specifically, the method involves injecting or otherwise administering the dendritic cells directly into a solid tumor. Treating a tumor in accordance with the embodiments of the present invention provides dendritic cells with more direct access to the tumor than that which is possible with conventional methods; especially those conventional methods wherein dendritic cells are administered peripherally. The techniques of the present invention may be particularly advantageous in instances where a tumor is surgically inoperable, where surgery is
otherwise undesirable, or where no portion of the tumor can be retrieved for priming dendritic cells ex vivo against the tumor; although such factors need not be indicated in order for the methods of the present invention to be effective. Owing in part to the difficulty in accessing and treating brain tumors with conventional surgical methods, the methods of the present invention may be especially advantageous in the treatment of tumors located in the brain of a mammal; particularly in treating high- or low-grade malignant gliomas, and, even more particularly, in treating anaplastic astrocytoma or glioblastoma multiforme. However, it should be recognized that numerous other types of tumors, and especially solid tumors, located in a variety of locations throughout the body of a patient may be treated in accordance with the methods of the present invention. Such other locations may include, but are in no way limited to, the skin (e.g., melanomas), breast, gastrointestinal tract, or respiratory tract. The composition and methods of the present invention are based, in part, on the inventors' surprising discovery that unprimed dendritic cells may be delivered to the tumor region of a patient and may thereafter be effective in the treatment of the tumor. Dendritic cells administered in this manner essentially prime themselves in vivo upon coming into contact or otherwise establishing biochemical communication with the target tumor cells, and, correspondingly, their antigen proteins. Unprimed dendritic cells include those dendritic cells that do not rely upon the acquisition of tumor tissue as a protein source, and the subsequent culturing therewith. In conventional methods, as discussed above, dendritic cells are primed ex vivo. This generally involves culturing the dendritic cells with the tumor cells against which they will subsequently be utilized. This process provides the dendritic cells access to the tumor proteins, thereby allowing the cells to process the associated tumor antigens and prepare to present the digested antigens to T-cells upon introduction of the dendritic cells to the body of a patient. However, in various embodiments of the present invention, dendritic cells may be delivered directly into a tumor bed or tumor region without first being primed ex vivo; the dendritic cells process the tumor antigens only in vivo. Dendritic cells suitable for use in accordance with the present invention may be isolated or obtained from any tissue in which such cells are found, or may be otherwise cultured and provided. In particular, antigen-presenting dendritic cells are preferred for use in accordance with the methods of the present invention. Such dendritic cells may be found, by way of example, in the bone marrow or peripheral blood mononuclear cells
(PBMCs) of a mammal, in the spleen of a mammal, or in the skin of a mammal (i.e., Langerhan's cells, which possess certain qualities similar to that of dendritic cells, may be found in the skin and may further be employed in conjunction with the methods of the present invention, and are included within the scope of the term "dendritic cells" as used herein). In the most preferred embodiments of the present invention, cells obtained from the bone marrow of a mammal may be utilized. Therefore, in one embodiment of the present invention, bone marrow may be harvested from a mammal and cultured in a medium. Any suitable medium that promotes the growth of dendritic cells may be used in accordance with the present invention, and may be readily ascertained by one of skill in the art without undue experimentation. In one embodiment of the present invention, GM-CSF and/or IL-4 may be included in the above-described medium. Media may be at least partially replenished every few (e.g., two to four) days during the culturing process. After a suitable amount of time, clusters of dendritic cells may be apparent in the medium, and may be retrieved therefrom, either in individual clusters or in any other convenient amount. Quantities of dendritic cells may be subcultured, where desirable, to generate yet greater quantities of the same. Dendritic cells used in conjunction with the methods of the present invention may be delivered to a tumor region (e.g., a brain tumor, or the surrounding brain tissue) in a recipient by any suitable means. Such means of delivery may include, but are in no way limited to, injection, infusion, inoculation, direct surgical delivery, or any combination thereof. In a preferred embodiment of the present invention, dendritic cells may be administered to a mammal by direct inoculation via stereotactic surgery; a standard inoculation procedure known to those of skill in the art of neurosurgery. Further appropriate mechanisms for delivering dendritic cells to a tumor or its surrounding tissue will be readily apparent to one in the art without undue experimentation, and are contemplated as being within the scope of the present invention. The composition of the present invention may include unprimed dendritic cells in a pharmaceutical carrier. Any conventional pharmaceutical carrier may be used in accordance with the composition or methods of the present invention, and an appropriate carrier may be selected by one of skill in the art without undue experimentation. In one embodiment of the present invention, the pharmaceutical carrier is saline, although other carriers may be utilized depending upon the desired characteristics of the composition.
For example, one may formulate a composition differently in order to account for different delivery techniques for the composition, physiological differences among patients (e.g., sex, weight, age, etc.), or different types of tumors (e.g., brain, breast, lung, etc.), among other factors. The dendritic cells administered to a patient in accordance with the composition and methods of the present invention may be delivered in combination with any of a variety of additional substances and compounds. By way of example, the dendritic cells of the present invention may be administered to a patient along with any suitable carrier, vehicle, additive, excipient, pharmaceutical adjunct, or other suitable product, as will be readily ascertained and appreciated by one of skill in the art. Moreover, the dendritic cells of the present invention may be administered in conjunction with other therapeutic compounds or agents useful in the treatment of the tumor or the relief of pain associated with the tumor or treatment thereof. The quantity of dendritic cells appropriate for administration to a patient to effect the methods of the present invention and the most convenient route of such administration may be based upon a variety of factors, as may the formulation of the composition of the present invention . Some of these factors may include, but are in no way limited to, the physical characteristics of the patient (e.g., age, weight, sex, etc.), the physical characteristics of the tumor (e.g., location, size, rate of growth, accessibility, etc.), and the extent to which other therapeutic means are being simultaneously implemented along with the methods of the present invention (e.g., chemotherapy, beam radiation therapy, etc.). Notwithstanding the variety of factors one should consider in implementing the methods of the present invention to treat a tumor, in a preferred embodiment of the present invention, a patient may be administered with from about 105 to about 107 dendritic cells in from about 0.05 mL to about 0.30 mL saline in a single administration. Additional administrations may be necessary, depending upon the above-described and other factors, such as the severity of tumor pathology. In preferred embodiments of the present invention, from about one to about five administrations of 106 dendritic cells is performed at two-week intervals. In a preferred embodiment of the present invention, a mammal is treated with dendritic cells following or in conjunction with radiotherapy. While not wishing to be bound by any theory, it is believed that prior or simultaneous treatment with radiotherapy renders a dendritic cell vaccination more effective as is allows the dendritic cells to better
process dying tumor cells. Similarly, a chemotherapy regimen administered either prior to or simultaneous with dendritic cell vaccination therapy that induces tumor cells to undergo apoptosis (i.e., programmed cell death) may be beneficial. As used herein, "treating" a tumor includes, but is not limited to, ameliorating the tumor, lessening the severity of its complications, causing it to decrease in mass and/or size, preventing it from manifesting, preventing it from recurring, merely preventing it from worsening, or a therapeutic effort to effect any of the aforementioned, even if such therapeutic effort is ultimately unsuccessful. EXAMPLES The Examples discussed herein demonstrate that dendritic cells may inhibit the growth of brain tumors when implanted directly into the tumors, and that this treatment may prolong the life of a patient with a brain tumor. The Examples further illustrate that dendritic cell vaccination may induce immune cell infiltration into brain tumors and systemic lymph nodes. Moreover, the Examples show that the implantation of dendritic cells directly into tumors disposed in locations throughout the body of a mammal is effective in the treatment of the same.
EXAMPLE 1 Intracranial Dendritic Cell Vaccination of Brain Tumors Bone marrow was harvested from the femurs and tibias of adult Fisher rats. Cells were plated in 24 well plates at a density of 1 million cells per well in RMPI 1640 medium (obtained from Gibco BRL; Gaithersburg, MD; hereinafter "Gibco") in media containing GM-CSF and IL-4 (both available from R and D Systems; Minneapolis, MN; hereinafter "R and D"). Media was partially replenished every three days. After eight days, clusters of enlarged floating/partially adherent dendritic cells were apparent. These cells were collected separately and their phenotypic profiles assessed using flow immunocytometry. They were positive for MHC class II and B7 co-stimulatory molecules; thereby confirming that the cells were dendritic in nature (Fig. 1).
EXAMPLE 2 Dendritic Cells Inhibit Tumor Growth when Inoculated Intratum orally Dendritic cells were inoculated subcutaneously along with a mixture of irradiated
and viable 9L glioma cells into the dorsum of the right foot of adult Fisher rats . Two weeks following this procedure, a second dose of dendritic cells was inoculated into each growing tumor. Eight weeks following t ie second dendritic cell vaccination, tumor sizes were measured using a precision caliper. Tumors were markedly smaller in animals that had received intratumoral dendritic cell
as compared to the control animals that received only saline inoculations (Fig. 2).
E.XAMPLE 3 Dendritic Cell Vaccination Induces Immune Cell (T-cell) Infiltration into Brain Tumors Dendritic cells were inoculated intracranially along with a mixture of irradiated and viable 9L glioma cells into the right corpus striatum (basal ganglia) of adult Fisher rats. Two weeks following this procedure, a second dose of dendritic cells was inoculated into each growing tumor. Two weeks following the second dendritic cell vaccination, animals were euthanized and their brains harvested. The brains were immediately frozen and sectioned on a cryostat (available from Janis Research Company, Inc.; Wilmington, MA). Slide mounted sections were stained for T-cell markers (i.e., CD4 and CD8). Tumors from dendritic cell vaccinated animals displayed increased quantities of infiltrating T-cells as compared to tumors from control animals that received only saline inoculations (Fig. 3).
EXAMPLE 4 Dendritic Cell Vaccinations Prolong Survival in Brain Tumor Bearing Rats Dendritic cells were inoculated intracranially along with a mixture of irradiated and viable 9L glioma cells into the right corp us striatum (basal ganglia) of adult Fisher rats. Two weeks following this procedure, a second dose of dendritic cells was inoculated into each growing tumor. Control animals were treated at similar time points with intracranial saline inoculations. Animals were followed for survival. Rats treated with intracranial dendritic cell vaccination survived longer than saline treated controls, with 75% of dendritic cell-treated animals surviving beyond 90 days after the initial tumor implantation compared to 5% of the control group (Fig. 4).
EXAMPLE 5 Dendritic Cell Vaccinations Prolong Survival in Rats with Established Brain Tumors A mixture of irradiated and viable 9L glioma cells was introduced into the right corpus striatum (basal ganglia) of adult Fisher rats. Two days later, rats were inoculated intracranially with dendritic cells. Control animals were treated at similar time points with intracranial monocyte/macrophage inoculations. Animals were followed for survival. Rats treated with intracranial dendritic cell vaccination survived longer than monocyte/macrophage-treated controls, with 60% of dendritic cell-treated animals surviving beyond 90 days after the initial tumor implantation compared to 10% of the control group (Fig. 5). Moreover, surviving rats were immune to intracranial tumor re- challenge.
EXAMPLE 6 Dendritic Cell Vaccinations Promote T-cell Infiltration into Brain Tumors A mixture of irradiated and viable 9L glioma cells was introduced into the right corpus striatum (basal ganglia) of adult Fisher rats. Rats were vaccinated with intratumoral inoculations of immature dendritic cells, monocytes, or saline on days 2 and 16 following tumor implantation. One week following the second intratumoral inoculation, tumors were harvested and stained for CD4+ and CD8+ T-cell content. Results indicated strong T-cell infiltration in animals vaccinated with dendritic cells (Fig. 6A) and weak infiltration in monocyte (Fig. 6B) and saline (Fig. 6C) treated controls.
EXAMPLE 7 Dendritic Cells Migrate to Systemic Lymph Nodes To assess whether dendritic cells inoculated into intracranial brain tumors could drain to the lymphatic system, deep cervical lymph nodes were harvested from rats that had received intracranial co-implantations of partially irradiated 9L glioma cells and green fluorescent protein (GFP) expressing dendritic cells four days earlier. Tumor bearing brain sections from these animals demonstrated GFP positive dendritic cells interspersed within the main tumor mass (Fig. 7A). Deep cervical lymph nodes ipsilateral to the site of implantation were infiltrated with numerous GFP expressing cells (Fig. 7B). In contrast,
contralateral cervical lymph node tissue (not shown) or lymph nodes from 9L glioma bearing rats not inoculated with dendritic cells (Fig. 7C) did not reveal any GFP positivity.
EXAMPLE 8 Enhancement of Tumor-Specific Cytotoxic T-cell Activity with Dendritic Cell Inoculation, Measured by Increased IFN-gamma Message Brain tumor-bearing rats were teated with intratumoral inoculations of dendritic cells, monocytes, or saline (n=4 per group), on days 2 and 16 following tumor implantation. T-cells were isolated from their spleens two weeks following the second intratumoral inoculation. Harvested T-cells were re-stimulated in quadruplicate in vitro with irradiated 9L glioma cells. Two such re-stimulations, each lasting 7 days, were performed on each sample, at the end of which T-cells were either exposed to freshly irradiated 9L glioma cells (Fig. 8, "Target") or were not re-exposed (Fig. 8, "No Target"). Four hours following re-exposure, RNA was harvested from T-cells and analyzed by means of a quantitative polymerase chain reaction (PCR) to detect levels of IFN- gamma message. All samples were also analyzed for CD8 RNA message content, which was used as an internal control, against which IFN-gamma message levels were normalized. Differences in IFN-gamma message levels were compared on the basis of the PCR cycle at which a particular cycle crossed an established threshold. A cycle difference of 1 was assumed to indicate a two-fold difference in the message. Following normalization against CD8 message, a fold-increase in IFN-gamma message for each treatment group was calculated by comparing target with no target. As depicted in Fig. 8, T-cells from animals inoculated with dendritic cells demonstrated a 1.48-fold increase in IFN-gamma RNA message compared to monocyte (1.12-fold) and saline (1.20-fold) treated controls.
EXAMPLE 9 Enhancement of Tumor-Specific Cytotoxic T-cell Activity with Dendritic Cell Inoculation, Measured by Increased IFN-gamma Secretion Brain tumor-bearing rats were teated with intratumoral inoculations of dendritic cells, monocytes, or saline (n=4 per group), on days 2 and 16 following tumor implantation. T-cells were isolated from their spleens two weeks following the second
intratumoral inoculation. Harvested T-cells were re-stimulated in quadruplicate in vitro with irradiated 9L glioma cells. Two such re-stimulations, each lasting 7 days, were performed on each sample, at the end of which T-cells were either exposed to freshly irradiated 9L glioma cells (Fig. 8, "Target") or were not re-exposed (Fig. 8, "No Target"). Twenty-four hours following re-exposure, media was harvested from T-cell cultures and analyzed by means of an emzyme-linked immunosorbent assay (ELISA) to quantify IFN-gamma protein secretion. For control purposes, media from re-stimulated T-cells from animals that were not implanted with brain tumors and were therefore never treated (Fig. 9, "No Tumor" group) were also analyzed. A fold-increase in IFN-gamma levels for each treatment group was calculated by comparing target with no target. As depicted in Fig. 9, T-cells from animals inoculated with dendritic cells demonstrated a 1.31-fold increase in secreted IFN-gamma compared to monocyte (0.70-fold) and saline (1.10-fold) treated controls. While the description above refers to particular embodiments of the present invention, it will be understood that many modifications may be made without departing from the spirit thereof. For instance, the protease inhibitors of the present invention may be used in the treatment of any number of conditions where inflammation is observed, as would be readily recognized by one skilled in the art and without undue experimentation. The accompanying claims are intended to cover such modifications as would fall within the true scope and spirit of the present invention. The presently disclosed embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims, rather than the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
Claims
1. A method for treating a tumor in a mammal, comprising: administering dendritic cells into a region selected from the group consisting of the tumor, tissue surrounding the tumor, and both the tumor and the tissue surrounding the tumor.
2. The method of claim 1 , wherein the dendritic cells are unprimed dendritic cells.
3. The method of claim 1 , wherein the tumor is a brain tumor and the tissue surrounding the tumor includes at least a portion of the brain of the mammal.
4. The method of claim 1 , wherein the tumor is a breast tumor and the tissue surrounding the tumor includes at least a portion of the breast of the mammal.
5. The method of claim 1 , wherein the tumor is a gastrointestinal tumor and the tissue surrounding the tumor includes at least a portion of the gastrointestinal tract of the mammal.
6. The method of claim 1 , wherein the tumor is a respiratory tumor and the tissue surrounding the tumor includes at least a portion of the respiratory tract of the mammal.
7. The method of claim 1 , further comprising harvesting the dendritic cells from a mammal prior to administering the dendritic cells.
8. The method of claim 7, wherein harvesting the dendritic cells from a mammal further includes harvesting the dendritic cells from a source selected from the group consisting of bone marrow of the mammal, peripheral blood mononuclear cells (PMBCs) of the mammal, the spleen of the mammal, and the skin of the mammal.
9. The method of claim 7, further comprising culturing the dendritic cells in a medium after harvesting the dendritic cells.
10. The method of claim 9, wherein the medium comprises granulocyte-macrophage colony-stimulating factor (GM-CSF).
11. The method of claim 9, wherein the med ϊum comprises interleukin-4 (IL-4).
12. The method of claim 9, wherein culturing the dendritic cells in the medium further includes periodically replenishing the medium.
13. The method of claim 9, wherein clusters of dendritic cells form in the medium, and culturing the dendritic cells in the medium further includes collecting the clusters.
14. The method of claim 1 , wherein administering the dendritic cells further includes using an administration technique selected from the group consisting of injection, infusion, inoculation, direct surgical delivery, direct inoculation via stereotactic surgery, and a combination thereof.
15. The method of claim 1 , wherein administering the dendritic cells further includes administering the dendritic cells in an amount of from about 105 to about 107 dendritic cells in from about 0.05 mL to about 0.30 mL saline.
16. The method of claim 1 , wherein administering the dendritic cells further includes performing multiple administrations of the dendritic cells.
17. The method of claim 16, wherein the mu Itiple administrations are performed at an interval of about two weeks.
18. The method of claim 1 , wherein the tumor is surgically inoperable.
19. The method of claim 1 , wherein the tumor is a solid tumor.
20. The method of claim 1 , further comprising administering radiation therapy to the mammal.
21. The method of claim 1 , further comprising administering chemotherapy to the mammal.
22. A method for inducing immune cell infiltration into a tumor in a mammal, comprising: administering dendritic cells into a region selected from the group consisting of the tumor, tissue surrounding the tumor, and both the tumor and the tissue surrounding the tumor.
23. The method of claim 22, wherein the dendritic cells are unprimed dendritic cells.
24. The method of claim 22, wherein the tumor is a brain tumor and the tissue surrounding the tumor includes at least a portion of the brain of the mammal.
25. The method of claim 22, wherein the tumor is a breast tumor and the tissue surrounding the tumor includes at least a portion of the breast of the mammal.
26. The method of claim 22, wherein the tumor is a gastrointestinal tumor and the tissue surrounding the tumor includes at least a portion of the gastrointestinal tract of the mammal.
27. The method of claim 22, wherein the tumor is a respiratory tumor and the tissue surrounding the tumor includes at least a portion of the respiratory tract of the mammal.
28. The method of claim 22, further comprising harvesting the dendritic cells from a mammal prior to administering the dendritic cells.
29. The method of claim 28, wherein harvesting the dendritic cells from a mammal further includes harvesting the dendritic cells from a source selected from the group consisting of bone marrow of the mammal, peripheral blood mononuclear cells (PMBCs) of the mammal, the spleen of the mammal, and the skin of the mammal.
30. The method of claim 28, further comprising culturing the dendritic cells in a medium after harvesting the dendritic cells.
31. The method of claim 30, wherein the medium comprises granulocyte-macrophage colony-stimulating factor (GM-CSF).
32. The method of claim 30, wherein the medium comprises interleukin-4 (IL-4).
33. The method of claim 30, wherein culturing the dendritic cells in the medium further includes periodically replenishing the medium.
34. The method of claim 30, wherein clusters of dendritic cells form in the medium, and culturing the dendritic cells in the medium further includes collecting the clusters.
35. The method of claim 22, wherein administering the dendritic cells further includes using an administration technique selected from the group consisting of injection, infusion, inoculation, direct surgical delivery, direct inoculation via stereotactic surgery, and a combination thereof.
36. The method of claim 22, wherein administering the dendritic cells further includes administering the dendritic cells in an amount of from about 105 to about 107 dendritic cells in from about 0.05 mL to about 0.30 mL saline.
37. The method of claim 22, wherein administering the dendritic cells further includes performing multiple administrations of the dendritic cells.
38. The method of claim 37, wherein the multiple administrations are performed at an interval of about two weeks.
39. The method of claim 22, wherein the tumor is surgically inoperable.
40. The method of claim 22, wherein the tumor is a solid tumor.
41. The method of claim 22, further comprising administering radiation therapy to the mammal.
42. The method of claim 22, further comprising administering chemotherapy to the mammal.
43. A composition for treating a tumor, comprising: unprimed dendritic cells; and a pharmaceutical carrier.
44. The composition of claim 43, wherein the unprimed dendritic cells are harvested from a source in a mammal.
45. The composition of claim 44, wherein the source is selected from the group consisting of bone marrow of the mammal, peripheral blood mononuclear cells (PMBCs) of the mammal, the spleen of the mammal, and the skin of the mammal.
46. The composition of claim 43, wherein the pharmaceutical carrier is saline.
47. The composition of claim 46, further comprising from about 105 to about 107 unprimed dendritic cells and from about 0.05 mL to about 0.30 mL saline.
48. The composition of claim 43, wherein the unprimed dendritic cells are grown in a medium.
49. The composition of claim 48, wherein the medium comprises granulocyte- macrophage colony-stimulating factor (GM-CSF).
50. The composition of claim 48, wherein the medium comprises interleukin-4 (IL-4).
51. The composition of claim 43 further comprising an additional component selected from the group consisting of a carrier, a vehicle, an additive, an excipient, a pharmaceutical adjunct, a therapeutic compound or agent useful in the treatment of the tumor, and a therapeutic compound or agent useful in the relief of pain.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2004/001612 WO2005079581A1 (en) | 2004-01-20 | 2004-01-20 | Intratumoral delivery of dendritic cells |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1705992A1 true EP1705992A1 (en) | 2006-10-04 |
Family
ID=34887924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04703716A Withdrawn EP1705992A1 (en) | 2004-01-20 | 2004-01-20 | Intratumoral delivery of dendritic cells |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1705992A1 (en) |
WO (1) | WO2005079581A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1676132B1 (en) | 2003-10-21 | 2014-01-22 | Cedars-Sinai Medical Center | Combination of chemotherapy and administration of glioma-antigen-pulsed dendritic cells in the treatment of glioma |
US8129184B2 (en) | 2006-09-26 | 2012-03-06 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
CA2700436C (en) | 2006-09-28 | 2017-04-18 | John S. Yu | Cancer vaccines and vaccination methods |
DK2328923T3 (en) | 2008-09-02 | 2016-03-21 | Cedars Sinai Medical Center | CD133 epitopes |
PT2427485T (en) | 2009-05-07 | 2017-03-13 | Immunocellular Therapeutics Ltd | Cd133 epitopes |
WO2014004809A2 (en) * | 2012-06-27 | 2014-01-03 | Hasumi International Research Foundation | Therapy and method for intratumorally introducing cytotoxic t lymphocyte and/or nkt cell with anti-tnf and/or anti-il-10 |
WO2014127296A1 (en) | 2013-02-14 | 2014-08-21 | Immunocellular Therapeutics, Ltd | Cancer vaccines and vaccination methods |
CA3029813A1 (en) | 2016-06-13 | 2017-12-21 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
EP3678701A4 (en) | 2017-09-05 | 2021-12-01 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
US10508262B1 (en) | 2018-06-29 | 2019-12-17 | Breakthrough Tech Llc | Activation of immune cells |
-
2004
- 2004-01-20 WO PCT/US2004/001612 patent/WO2005079581A1/en not_active Application Discontinuation
- 2004-01-20 EP EP04703716A patent/EP1705992A1/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO2005079581A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2005079581A1 (en) | 2005-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ali et al. | In situ regulation of DC subsets and T cells mediates tumor regression in mice | |
US6277368B1 (en) | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine | |
Um et al. | Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer | |
US11801259B2 (en) | Methods and compositions for treating cancers using antisense | |
US20040057935A1 (en) | Intratumoral delivery of dendritic cells | |
CN101072582B (en) | Alpha thymosin peptides as cancer vaccine adjuvants | |
JP2024019229A (en) | Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers | |
WO2005079581A1 (en) | Intratumoral delivery of dendritic cells | |
Pollack et al. | Exploitation of immune mechanisms in the treatment of central nervous system cancer | |
US20210353674A1 (en) | Pharmaceutical composition for use in the treatment of pancreatic cancer | |
Banchereau | Dendritic cells: therapeutic potentials | |
WO2017152008A1 (en) | Development of dual whole cell-based vaccine against pancreatic cancer | |
WO2002053176A2 (en) | An autologous anti-cancer vaccine | |
Tjoa et al. | Progress in active-specific immunotherapy of brain malignancies | |
Clavreul et al. | Effects of syngeneic cellular vaccinations alone or in combination with GM-CSF on the weakly immunogenic F98 glioma model | |
Bora et al. | Clinical development in dendritic cell based immunotherapy | |
KR20060116850A (en) | Intratumoral delivery of dendritic cells | |
Couldwell et al. | Im m unology and Im m unotherapy of Intrinsic G lial Tum ors | |
Zhang et al. | Mechanisms of action of dendritic cell vaccines for the treatment of cancer | |
RU2203683C1 (en) | Method for immunotherapy with medullary dendrite cells in patients with solid tumors | |
He et al. | Anti-tumor immune responses in immune-reconstituted mice injected with a tumor vaccine | |
Baogang et al. | Fixed-tumor vaccine: a practical formulation with cytokine-microspheres for protective and therapeutic antitumor immunity | |
Marits et al. | Sentinel node-based immunotherapy of colon cancer | |
SCHREIBER | Genetically Engineered Vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060717 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: YU, JOHN, S. Inventor name: EHTESHAM, MONEEB Inventor name: BLACK, KEITH |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20070124 |